Working… Menu
Trial record 31 of 182 for:    carfilzomib OR pr-171

Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02047253
Recruitment Status : Completed
First Posted : January 28, 2014
Results First Posted : December 19, 2018
Last Update Posted : December 19, 2018
Information provided by (Responsible Party):
Guru Sonpavde, MD, University of Alabama at Birmingham

Brief Summary:
This study will test how effective the drug, Carfilzomib, reduces progression of prostate cancer in patients who have previously received chemotherapy and androgen inhibitors. Carfilzomib is approved for multiple myeloma but is not approved for prostate cancer. Therefore, it is considered investigational. Other approved methods of treatment for metastatic prostate cancer have demonstrated only modest benefits. Novel and tolerable agents are necessary to make further gains and extend overall survival.

Condition or disease Intervention/treatment Phase
Metastatic Castration-resistant Prostate Cancer Drug: Carfilzomib Drug: Dexamethasone Drug: Acyclovir Phase 2

Detailed Description:

First-line chemotherapy for metastatic castration-resistant prostate cancer (CRPC) combined with androgen inhibitors modestly extends overall survival. Carfilzomib is anticipated to enhance progression-free survival (PFS) as well as reduce pain and toxicities.

Proteasome inhibitors are promising agents used in the therapy of prostate cancer. Carfilzomib is a more potent and irreversible proteasome inhibitor than the frequently used proteasome inhibitor, Bortezomib. In Phase I trials Carfilzomib demonstrated substantial antitumor activity while exhibiting tolerable side effects.

Carfilzomib has been approved by the FDA for patients with multiple myeloma. The drug, however, is not approved for the use with CRPC patients. This trial will evaluate the tolerance and effectiveness of Carfilzomib in men with metastatic progressive CRPC following chemotherapy and androgen inhibitors.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Chemotherapy and Androgen Pathway Inhibitors
Actual Study Start Date : April 2014
Actual Primary Completion Date : June 8, 2017
Actual Study Completion Date : July 14, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Carfilzomib
Carfilzomib is administered twice-weekly on consecutive days (days 1, 2, 8, 9, 15, 16) as a 30-minute intravenous infusion for 3 weeks every 4 weeks (1 cycle) with dexamethasone given as pre-medication. The dose of carfilzomib is 20 mg/m2 on days 1 and 2 of cycle 1 and is then escalated in succeeding weeks and cycles to 56 mg/m2 if no dose limiting toxicities occur. Acyclovir is given orally at 400 mg twice daily during therapy but may be discontinued at some point. Therapy will continue until side effects become unacceptable, the disease progresses, or the doctor withdraws the patient.
Drug: Carfilzomib
Carfilzomib will be administered on days 1, 2, 8, 9, 15, 16 within each 4 week cycle.
Other Name: Kyprolis

Drug: Dexamethasone
Administered prior to administration of Study drug

Drug: Acyclovir
Administered orally twice daily
Other Name: Zovirax

Primary Outcome Measures :
  1. Progression-free Survival (PFS) [ Time Frame: Baseline through 6 months for evaluating all patients ]
    The study will measure patient survival at 6 months but will continue to monitor overall survival as a secondary objective. The Kaplan-Meier method will be used.

  2. Overall Survival [ Time Frame: From baseline through 36 months. ]
    Outcome measure was completed by using a count of participants.

Secondary Outcome Measures :
  1. Number of Participants With Prostate-Specific Antigen (PSA) Changes [ Time Frame: Baseline through 36 months ]
    PSA levels were collected at each visit on the day of treatment. Linear regression with PSA as the dependent variable and time as the dependent variable was performed.

  2. Number of Participants With Circulating Tumor Cell (CTC) Decline Over Three Time Points (Before Study Initiation, Day 1 of Cycles 2 and 4 [ Time Frame: Baseline through 36 months ]

    The CTC marker will be used to evaluate efficacy of response to treatment. CTC changes will include changes from unfavorable (less than or equal to 5/7.5 ml) to favorable and declines by >30%.

    Three collections: before study initiation, Day 1 of Cycles 2 and 4

  3. Assessment of Toxicities [ Time Frame: Baseline through 36 months ]

    Hematologic and non-hematologic toxicities will be graded. The new international criteria proposed by the Response Evaluation Criteria In Solid Tumors (RECIST) will serve as the guideline.

    On Day 1 of each cycle (4 weeks) for the duration of treatment and then 30 days following the last treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically proven adenocarcinoma of the prostate
  • Metastatic disease
  • Progressive disease (PSA, radiologic, symptomatic) following abiraterone acetate and/or Enzalutamide (prior sipuleucel-T and chemotherapy are allowed); PSA progression is defined as baseline increase followed by any PSA increase ≥1 week apart.
  • Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
  • Patients, even if surgically sterilized (i.e., status post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourse if female partner of childbearing age.
  • An elevated PSA level of >2ng/mL for patients progressing by PSA criteria is required (last confirmatory sample must be >2ng/mL)
  • Currently on androgen ablation hormone therapy (a luteinizing hormone- releasing hormone (LHRH) agonist/antagonist or orchiectomy) with testosterone level <50ng/dL)
  • Has an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 - 2
  • Left ventricular ejection fraction (LVEF) ≥40% on 2-D transthoracic echocardiogram (ECHO); Multi-gated Acquisition Scan (MUGA) is acceptable if ECHO is not available.
  • ≥19 years of age
  • Resolution of all acute toxic effects of prior chemotherapy or surgical procedures to NCI CTCAE Version 4.03 Grade <1, in the opinion of the treating physician.
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Patient has a platelet count of <100,000/mm3, or absolute neutrophil count of <1500/mm3 or Hemoglobin <8.0gm/dL
  • Patient has a calculated or measured creatinine clearance of <30 milliliters (mL)/minute
  • Patient has total bilirubin >2 x upper limit of normal (ULN), or aspartate aminotransferase (AST), alanine aminotransferase (ALT) >3.5 x ULN
  • Patient has ≥ Grade 2 peripheral neuropathy within 14 days before enrollment
  • Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Before study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant.
  • Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial.
  • Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
  • Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of: a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the breast; c) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas.
  • Known HIV, hepatitis B and hepatitis C infection
  • Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to randomization
  • Prior treatment with bortezomib
  • Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize Carfilzomib)
  • Has received prior radiation to >50% of the bone marrow
  • Has had significant bleeding/thrombosis in previous 4 weeks
  • Has received treatment with radiation therapy, surgery, chemotherapy, or an investigational agent within 4 weeks prior to registration, (6 weeks for radiation therapy, radionuclides, nitrosoureas, or Mitomycin C) or who have not recovered from adverse events due to agents administered more than 4 weeks earlier
  • Has evidence of uncontrolled Central Nervous System (CNS) involvement (previous radiation and off steroids is acceptable)
  • Patients may not be receiving any other investigational agents
  • Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection
  • Is unable to comply with study requirements
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02047253

Layout table for location information
United States, Alabama
Birmingham VA Medical Center
Birmingham, Alabama, United States, 35233
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
United States, Georgia
Cancer Life Center, Navicent Health
Macon, Georgia, United States, 31210
United States, Louisiana
University of Tulane
New Orleans, Louisiana, United States, 70118
Sponsors and Collaborators
University of Alabama at Birmingham
Layout table for investigator information
Principal Investigator: Guru Sonpavde, MD University of Alabama at Birmingham
Study Chair: Mansoor Saleh, MD Georgia Cancer Specialists
  Study Documents (Full-Text)

Documents provided by Guru Sonpavde, MD, University of Alabama at Birmingham:

Layout table for additonal information
Responsible Party: Guru Sonpavde, MD, Principal Investigator, University of Alabama at Birmingham Identifier: NCT02047253     History of Changes
Other Study ID Numbers: F130725012 (UAB 1336)
First Posted: January 28, 2014    Key Record Dates
Results First Posted: December 19, 2018
Last Update Posted: December 19, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Guru Sonpavde, MD, University of Alabama at Birmingham:
prostate cancer
PSA (prostate-specific antigen)
CRPC (castration-resistant prostate cancer)
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Dexamethasone acetate
BB 1101
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents